Total Payments
$493,139
2024 Payments
$32,064
Companies
63
Transactions
3,939
Medicare Patients
845
Medicare Billing
$174,484
Payment Breakdown by Category
Other$325,894 (66.1%)
Food & Beverage$74,633 (15.1%)
Travel$48,438 (9.8%)
Consulting$43,567 (8.8%)
Education$607.88 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $323,894 | 198 | 65.7% |
| Food and Beverage | $74,633 | 3,518 | 15.1% |
| Travel and Lodging | $48,438 | 110 | 9.8% |
| Consulting Fee | $43,567 | 27 | 8.8% |
| Honoraria | $2,000 | 1 | 0.4% |
| Education | $607.88 | 85 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $118,816 | 389 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $115,707 | 394 | $0 (2024) |
| Amarin Pharma Inc. | $65,204 | 333 | $0 (2023) |
| IRONWOOD PHARMACEUTICALS, INC | $44,746 | 100 | $0 (2020) |
| ABBVIE INC. | $40,592 | 246 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $23,259 | 252 | $0 (2024) |
| Kowa Pharmaceuticals America, Inc. | $20,859 | 137 | $0 (2023) |
| Bayer Healthcare Pharmaceuticals Inc. | $11,828 | 92 | $0 (2024) |
| EISAI INC. | $8,299 | 42 | $0 (2022) |
| Novo Nordisk Inc | $8,244 | 203 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $32,064 | 359 | AstraZeneca Pharmaceuticals LP ($12,199) |
| 2023 | $14,489 | 345 | AstraZeneca Pharmaceuticals LP ($3,213) |
| 2022 | $26,231 | 428 | Amgen Inc. ($8,267) |
| 2021 | $34,223 | 492 | Amgen Inc. ($14,479) |
| 2020 | $36,543 | 415 | Amgen Inc. ($23,783) |
| 2019 | $108,987 | 596 | Amgen Inc. ($50,369) |
| 2018 | $119,510 | 618 | Ironwood Pharmaceuticals, Inc ($37,922) |
| 2017 | $121,093 | 686 | Janssen Pharmaceuticals, Inc ($66,630) |
All Payment Transactions
3,939 individual payment records from CMS Open Payments — Page 1 of 158
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $9.75 | General |
| Category: RESPIRATORY | ||||||
| 12/26/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $0.06 | General |
| Category: RESPIRATORY | ||||||
| 12/23/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,350.00 | General |
| Category: Respiratory | ||||||
| 12/23/2024 | PFIZER INC. | PAXLOVID (Drug) | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 12/23/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $17.62 | General |
| Category: Respiratory | ||||||
| 12/20/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $22.96 | General |
| Category: Endocrinology | ||||||
| 12/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,245.00 | General |
| Category: Cardio-renal | ||||||
| 12/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $415.00 | General |
| Category: Cardio-renal | ||||||
| 12/19/2024 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $23.93 | General |
| Category: Bone Health | ||||||
| 12/19/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $16.06 | General |
| Category: Respiratory | ||||||
| 12/18/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $6.49 | General |
| Category: Endocrinology | ||||||
| 12/17/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: RESPIRATORY | ||||||
| 12/17/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $6.16 | General |
| Category: Inflammation | ||||||
| 12/16/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $27.06 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $13.24 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/14/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $27.80 | General |
| Category: Diabetes | ||||||
| 12/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $24.98 | General |
| Category: Cardio-renal | ||||||
| 12/12/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $22.48 | General |
| Category: Diabetes | ||||||
| 12/12/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $2.11 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/11/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $28.30 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/11/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $3.71 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $109.82 | General |
| Category: Respiratory | ||||||
| 12/10/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $20.07 | General |
| Category: Cardio-renal | ||||||
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,350.00 | General |
| Category: Respiratory | ||||||
| 12/09/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $16.48 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 156 | 565 | $69,804 | $37,450 |
| 2022 | 8 | 229 | 727 | $87,023 | $47,450 |
| 2021 | 7 | 230 | 667 | $78,159 | $45,333 |
| 2020 | 8 | 230 | 1,979 | $89,724 | $44,250 |
Total Patients
845
Total Services
3,938
Medicare Billing
$174,484
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 106 | 505 | $58,075 | $31,321 | 53.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 36 | 36 | $8,969 | $4,465 | 49.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 14 | 24 | $2,760 | $1,664 | 60.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 116 | 604 | $69,460 | $38,174 | 55.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 30 | 30 | $6,750 | $4,147 | 61.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 22 | 24 | $4,320 | $2,300 | 53.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 12 | 12 | $2,340 | $951.56 | 40.7% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2022 | 13 | 13 | $2,105 | $659.35 | 31.3% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 11 | 11 | $785.00 | $619.13 | 78.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 14 | 14 | $550.00 | $417.43 | 75.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 11 | 19 | $713.00 | $182.19 | 25.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 99 | 497 | $57,155 | $33,962 | 59.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 40 | 63 | $11,340 | $6,419 | 56.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 14 | 14 | $3,360 | $1,822 | 54.2% |
| 90662 | Vaccine for influenza for injection into muscle, split virus, preservation free | Office | 2021 | 20 | 20 | $1,305 | $1,235 | 94.7% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 14 | 14 | $2,730 | $1,021 | 37.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 25 | 25 | $980.00 | $464.75 | 47.4% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 18 | 34 | $1,289 | $408.64 | 31.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 21 | 1,500 | $37,500 | $21,899 | 58.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 86 | 310 | $35,407 | $16,587 | 46.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 34 | 62 | $10,100 | $3,436 | 34.0% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 14 | 14 | $2,715 | $677.46 | 25.0% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 15 | 16 | $980.00 | $524.95 | 53.6% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 26 | 39 | $1,482 | $466.57 | 31.5% |
| 90686 | Vaccine for influenza for administration into muscle, 0.5 ml dosage | Office | 2020 | 18 | 20 | $820.00 | $329.52 | 40.2% |
About Dr. Philip Suh, M.D
Dr. Philip Suh, M.D is a General Practice healthcare provider based in Honolulu, Hawaii. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1518934009.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Philip Suh, M.D has received a total of $493,139 in payments from pharmaceutical and medical device companies, with $32,064 received in 2024. These payments were reported across 3,939 transactions from 63 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($323,894).
As a Medicare-enrolled provider, Suh has provided services to 845 Medicare beneficiaries, totaling 3,938 services with total Medicare billing of $174,484. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty General Practice
- Location Honolulu, HI
- Active Since 03/02/2006
- Last Updated 10/25/2017
- Taxonomy Code 208D00000X
- Entity Type Individual
- NPI Number 1518934009
Products in Payments
- INVOKANA (Drug) $114,317
- Vascepa (Drug) $65,204
- Prolia (Biological) $63,010
- DUZALLO (Drug) $37,748
- Aimovig (Biological) $27,351
- EVENITY (Biological) $24,624
- Livalo (Drug) $20,582
- BREZTRI (Drug) $15,458
- Creon (Drug) $12,494
- Kerendia (Drug) $11,733
- Dayvigo (Drug) $8,299
- CREON (Drug) $8,218
- Xofluza (Drug) $7,655
- ZURAMPIC (Drug) $6,216
- AIRSUPRA (Drug) $4,120
- Rybelsus (Drug) $4,066
- Ozempic (Drug) $3,575
- Otezla (Drug) $3,004
- Androgel (Drug) $2,811
- JARDIANCE (Drug) $2,612
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
General Practice Doctors in Honolulu
Kent Hironaka, Dds, DDS
General Practice — Payments: $110,538
General Practice $110,538
Dr. Wynn Okuda, Dmd, DMD
General Practice — Payments: $103,117
General Practice $103,117
Dr. Jason Ako, D.d.s, D.D.S
General Practice — Payments: $80,751
General Practice $80,751
Dr. Russell Tacata, M.d, M.D
General Practice — Payments: $31,235
General Practice $31,235
Dr. Eugene Azuma, D.d.s, D.D.S
General Practice — Payments: $16,398
General Practice $16,398
Wade Takenishi, Dds, DDS
General Practice — Payments: $11,549
General Practice $11,549